자가 증폭 RNA 합성 시장 : 규모, 점유율 및 동향 분석 보고서 - 제품 및 서비스별, 용도별, 최종 용도별, 지역별 부문 예측(2025-2030년)

Self-amplifying RNA Synthesis Market Growth & Trends:

The global self-amplifying RNA synthesis market size is expected to reach USD 310.8 million by 2030 and is anticipated to grow at a CAGR of 19.24% from 2025 to 2030. This expansion is largely driven by the increasing demand for RNA-based vaccines and therapies, particularly during the COVID-19 pandemic. Researchers are turning to saRNA as a promising platform for rapid vaccine development due to its ability to induce a stronger immune response. The self-amplification feature of RNA allows for lower dosages and potentially fewer side effects, which is gaining traction in clinical trials. As a result, pharmaceutical companies are focusing on incorporating saRNA into their product pipelines, further boosting market growth.

The growing interest in personalized medicine is another key factor contributing to the market's expansion. With advancements in genomic technologies, there is an increasing need for tailored treatments targeting specific genetic profiles. Self-amplifying RNA technologies enable the development of vaccines and gene therapies that can be customized for individual patients. Furthermore, as healthcare systems shift toward more personalized care, the demand for innovative solutions such as saRNA will continue to rise.

In addition, the global rise in infectious diseases and the urgent need for new therapeutic options create a favorable environment for saRNA technologies. Beyond vaccines, self-amplifying RNA is being explored for various diseases, including cancer, genetic disorders, and autoimmune diseases. The ability of saRNA to be engineered for different applications allows for diverse therapeutic options, attracting substantial investment from the public and private sectors. Moreover, the ongoing advancements in RNA technology and the increasing number of clinical trials are expected to accelerate market adoption. This growing interest in multi-disease applications ensures a promising outlook for the global self-amplifying RNA synthesis market in the coming years.

Self-amplifying RNA Synthesis Market Report Highlights:

• Based on product & service, the custom synthesis services segment is expected to witness the fastest growth rate during the forecast period, due to the increasing demand for tailored RNA solutions, which are essential in the development of personalized medicines and RNA-based therapeutics.
• Based on an application, the therapeutics development segment dominated the market and accounted for the largest revenue share in 2024, driven by the surge in research and development of RNA-based therapeutics, such as vaccines and gene-editing tools, which have significantly contributed to the growth of this segment.
• Based on end use, the pharmaceutical & biotechnology companies segment held the largest revenue share in 2024. These companies are in charge of RNA therapeutic research, product development, and large-scale production, thus creating a substantial demand for RNA synthesis services. Their significant investments in RNA technology, particularly for vaccine production and genetic therapies, have positioned them as major players in the market. The growing number of RNA-based therapies in development, including novel vaccines and gene therapies, ensures that these companies remain the primary end-users of RNA synthesis solutions.
• Based on region, North America held the largest revenue share in 2024 in the self-amplifying RNA synthesis market, primarily driven by the region's strong pharmaceutical and biotechnology industries. The U.S. continues to lead RNA technology research, with significant investments in RNA-based therapeutics and vaccine development.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product & Service
  • 1.2.2. Application
  • 1.2.3. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Self-Amplifying RNA Synthesis Market Variables & Trends

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Advancements in RNA Technology
    • 3.2.1.2. Rising Demand for Personalized Medicine
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Manufacturing and Scalability Challenges
    • 3.2.2.2. Regulatory and Scientific Hurdles
• 3.3. Self-Amplifying RNA Synthesis Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Self-Amplifying RNA Synthesis Market: Product & Service Estimates & Trend Analysis

• 4.1. Product & Service Segment Dashboard
• 4.2. Global Self-Amplifying RNA Synthesis Market Product & Service Movement Analysis
• 4.3. Global Self-Amplifying RNA Synthesis Market Size & Trend Analysis, by Product & Service, 2018 to 2030 (USD Million)
• 4.4. Products
  • 4.4.1. Products Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
  • 4.4.2. Premade saRNA
    • 4.4.2.1. Premade saRNA Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
  • 4.4.3. Enzymes & Reagents
    • 4.4.3.1. Enzymes & Reagents Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
  • 4.4.4. Others
    • 4.4.4.1. Others Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
• 4.5. Custom Synthesis Services
  • 4.5.1. Custom Synthesis Services Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)

Chapter 5. Self-Amplifying RNA Synthesis Market: Application Estimates & Trend Analysis

• 5.1. Application Segment Dashboard
• 5.2. Global Self-Amplifying RNA Synthesis Market Application Movement Analysis
• 5.3. Global Self-Amplifying RNA Synthesis Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 5.4. Therapeutics Development
  • 5.4.1. Therapeutics Development Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
  • 5.4.2. Infectious Diseases
    • 5.4.2.1. Infectious Diseases Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
  • 5.4.3. Oncology
    • 5.4.3.1. Oncology Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
  • 5.4.4. Others
    • 5.4.4.1. Others Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
• 5.5. Biomedical Research
  • 5.5.1. Biomedical Research Techniques Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)

Chapter 6. Self-Amplifying RNA Synthesis Market: End Use Estimates & Trend Analysis

• 6.1. End Use Segment Dashboard
• 6.2. Global Self-Amplifying RNA Synthesis Market End Use Movement Analysis
• 6.3. Global Self-Amplifying RNA Synthesis Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 6.4. Pharmaceutical & Biotechnology Companies
  • 6.4.1. Pharmaceutical & Biotechnology Companies Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
• 6.5. Academic & Research Institutes
  • 6.5.1. Academic & Research Institutes Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
• 6.6. Other End Use
  • 6.6.1. Other End Use Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)

Chapter 7. Self-Amplifying RNA Synthesis Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Categorization
• 8.2. Company Market Position Analysis, 2024
• 8.3. Strategy Mapping
• 8.4. Participants Overview
  • 8.4.1. GenScript
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product & Service benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Creative Biogene
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product & Service benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. OZ Biosciences
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product & Service benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. BOC Sciences
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product & Service benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. Croyez Bioscience Co., Ltd.
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product & Service benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. Creative Biolabs
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product & Service benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. Maravai LifeSciences
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product & Service benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. Areterna LLC
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product & Service benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Applied DNA Sciences, Inc. (LineaRx)
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product & Service benchmarking
    • 8.4.9.4. Strategic initiatives